サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414322

インスリンバイオシミラーの世界市場レポート 2024年

Insulin biosimilars Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
インスリンバイオシミラーの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

インスリンバイオシミラーの市場規模は近年急速に拡大しています。2023年の26億4,000万米ドルから2024年には30億8,000万米ドルへとCAGR16.3％で拡大します。過去数年間に見られた拡大は、糖尿病有病率の上昇、医療費の高騰、糖尿病治療へのアクセスの拡大、市場競争、価格圧力に加え、規制当局の支援と合理化された承認経路によるものです。

ヘルスケア支出の増加は、インスリンバイオシミラー市場の成長を促進すると予想されます。ヘルスケア支出は、特定の時間枠内でのヘルスケア商品とサービスに対する総支出を表し、インスリンバイオシミラーに大きく影響され、費用対効果の高い代替手段を提供し、全体的なコスト削減に貢献します。例えば、2023年9月のメディケア＆メディケイド・サービスセンターによると、2022年から2031年までの国民医療費（NHE）の平均成長率の予測値は、GDPの平均成長率を上回ると予想されています。この成長予測により、国内総生産（GDP）に占める医療費の割合は2021年の18.3％から2031年には19.6％に増加し、インスリンバイオシミラー市場を牽引することになります。

2023年のインスリンバイオシミラー市場で最大の地域は北米です。アジア太平洋は、予測期間中、世界のインスリンバイオシミラー市場レポートにおいて最も急成長している地域になると予測されています。インスリンバイオシミラー市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のインスリンバイオシミラー市場、バイオシミラーの種類別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 速効型バイオシミラー
  • 長時間作用型バイオシミラー
  • プレミックス作用バイオシミラー
  • 世界のインスリンバイオシミラー市場、疾患適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • I型糖尿病
  • II型糖尿病
  • 世界のインスリンバイオシミラー市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のインスリンバイオシミラー市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院
  • 外来手術センター
  • その他のエンドユーザー

第7章 地域および国の分析

  • 世界のインスリンバイオシミラー市場、地域別、実績および予測、2018-2023、2023-2028年、2033年
  • 世界のインスリンバイオシミラー市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • インスリンバイオシミラー市場の競合情勢
  • インスリンバイオシミラー市場企業プロファイル
    • Eli Lilly and Company
    • Boehringer Ingelheim GmbH
    • Merck &Co Inc.
    • Pfizer Inc.
    • Biocon Ltd.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

目次
Product Code: r11832

“Insulin biosimilars Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on insulin biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for insulin biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The insulin biosimilars market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Biosimilars Type: Rapid Acting biosimilars; Long Acting biosimilars; Premixed Acting biosimilars
  • 2) By Disease Indication Type: Type I Diabetes; Type II Diabetes
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 4) By End User: Hospitals; Ambulatory Surgical Centers; Other End Users
  • Companies Mentioned: Eli Lilly and Company; Boehringer Ingelheim GmbH; Merck & Co Inc.; Pfizer Inc.; Biocon Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Insulin biosimilars denote biological products that closely resemble an existing reference insulin product in terms of quality, safety, and efficacy, which has already received approval and been introduced to the market. Widely employed to regulate blood glucose levels, insulin is indispensable for individuals managing diabetes to sustain healthy glucose levels.

The primary types of biosimilar insulin include rapid-acting biosimilars, long-acting biosimilars, and premixed-acting biosimilars. Rapid-acting biosimilars constitute a category of insulin biosimilar products engineered for swift onset of action and a relatively brief duration of activity. These biosimilars address various disease indications such as type I diabetes and type II diabetes, and they are distributed through diverse channels, including hospital pharmacies, retail pharmacies, and online pharmacies. The end-users encompass hospitals, ambulatory surgical centers, and other entities.

The insulin biosimilars market research report is one of a series of new reports from The Business Research Company that provides insulin biosimilars market statistics, including insulin biosimilars industry global market size, regional shares, competitors with an insulin biosimilars market share, detailed insulin biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the insulin biosimilars industry. This insulin biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The insulin biosimilars market size has grown rapidly in recent years. It will grow from $2.64 billion in 2023 to $3.08 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The expansion observed in the historical period can be ascribed to a heightened prevalence of diabetes, the escalation of healthcare costs, the widening accessibility to diabetes treatment, market competition, and price pressures, as well as regulatory support and streamlined approval pathways.

The insulin biosimilars market size is expected to see rapid growth in the next few years. It will grow to $5.41 billion in 2028 at a compound annual growth rate (CAGR) of 15.2%. The anticipated growth in the forecast period can be linked to the global burden of diabetes, the emergence of markets and expansion of access, policies favoring the adoption of biosimilars, patient preference for affordability, and increased collaborations and partnerships in the biopharmaceutical industry. Key trends expected in the forecast period encompass the diversification of insulin product portfolios, global market penetration, the integration of technology in insulin delivery, regulatory backing for biosimilars development, and the implementation of patient-centric approaches in product development.

The anticipated rise in the prevalence of diabetes is poised to drive the growth of the insulin biosimilars market in the future. Diabetes, a group of chronic metabolic disorders characterized by prolonged high blood sugar levels, has created a growing demand for insulin biosimilars as a crucial alternative for insulin therapy. For example, as of December 2021, the International Diabetes Federation (IDFT) projected an increase in the number of people with diabetes to 643 million by 2030 and 783 million by 2045. Additionally, there are currently over 1.2 million children and adolescents (aged 0-19 years) living with type 1 diabetes. This surge in diabetes prevalence serves as a driving force for the insulin biosimilars market.

The upward trajectory of healthcare expenditure is expected to fuel the growth of the insulin biosimilars market. Healthcare expenditure, representing the total spending on healthcare goods and services within a specific timeframe, is significantly influenced by insulin biosimilars, offering cost-effective alternatives and contributing to overall cost savings. For instance, according to the Centers for Medicare & Medicaid Services in September 2023, the projected average growth in National Health Expenditure (NHE) between 2022 and 2031 is expected to surpass the average GDP growth rate. This projected growth will result in an increased health spending share of Gross Domestic Product (GDP) from 18.3 percent in 2021 to 19.6 percent in 2031, thus driving the insulin biosimilars market.

Innovation in product development stands out as a prominent trend gaining traction in the insulin biosimilar market. Major market players are channeling their efforts into creating innovative products to solidify their market positions. For instance, in July 2021, Biocon Biologics, in collaboration with Viatris Inc., received approval from The U.S. Food and Drug Administration (FDA) for the first Interchangeable Biosimilar Semglee, a breakthrough product for the treatment of diabetes. This approval is significant as it covers both type 1 and type 2 diabetes in adults and pediatric patients aged 6 years and older, marking a crucial milestone for cost savings and improved access to affordable treatment options for diabetes sufferers.

Strategic partnerships have become a notable trend in major companies operating in the insulin biosimilar market, aiming to develop new products and fortify their market positions. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefits and success. For instance, in September 2023, Meitheal Pharmaceuticals partnered with Tonghua Dongbao Pharmaceutical to commercialize three insulin biosimilars, including insulin lispro, insulin glargine, and insulin aspart. This collaboration enables Meitheal Pharmaceuticals to broaden its product portfolio and enhance its global reach.

In November 2022, Biocon Biologics acquired Viatris' global biosimilars business for an undisclosed amount, taking over the portfolio of approved and pipeline biosimilar products, as well as dedicated R&D and manufacturing facilities. This strategic acquisition marked a significant milestone for Biocon Biologics, further consolidating its position in the biosimilars market. Viatris, a US-based pharmaceutical company specializing in insulin biosimilars, was the acquired entity.

Major companies operating in the insulin biosimilars market report are Eli Lilly and Company,Boehringer Ingelheim GmbH,Merck & Co Inc.,Pfizer Inc.,Biocon Ltd.,Mylan N.V.,Wockhardt Limited,NOVO Nordisk A/S,Sanofi S.A,Ypsomed AG,Fresenius Kabi AG,Sandoz International GmbH,Novartis International AG,Aurobindo Pharma Ltd.,Intas Pharmaceuticals Ltd.,Dr. Reddy's Laboratories Ltd.,Amgen Inc., Samsungbioepis Co. Ltd.,Coherus BioSciences Inc .,Teva Pharmaceutical Industries Ltd.,Stada Arzneimittel AG,Celltrion Inc.,Biogen Inc., AstraZeneca plc,Fujifilm Kyowa Kirin Biologics Co. Ltd.,Mochida Pharmaceutical Co. Ltd.,Daiichi Sankyo Company Limited,LG Chem Ltd.,JCR Pharmaceuticals Co. Ltd.,Green Cross Corporation,Lupin Limited,Torrent Pharmaceuticals Ltd.,Zydus lifescience Ltd.

North America was the largest region in the insulin biosimilars market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global insulin biosimilars market report during the forecast period. The regions covered in the insulin biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the insulin biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The insulin biosimilar market consists of sales of a variety of insulin types such as intermediate insulin, insulin glargine, and insulin analog. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Insulin biosimilars Market Characteristics

3. Insulin biosimilars Market Trends And Strategies

4. Insulin biosimilars Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Insulin biosimilars Market Size and Growth

  • 5.1. Global Insulin biosimilars Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Insulin biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Insulin biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Insulin biosimilars Market Segmentation

  • 6.1. Global Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Rapid Acting biosimilars
  • Long Acting biosimilars
  • Premixed Acting biosimilars
  • 6.2. Global Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Type I Diabetes
  • Type II Diabetes
  • 6.3. Global Insulin biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospitals
  • Ambulatory Surgical Centers
  • Other End Users

7. Insulin biosimilars Market Regional And Country Analysis

  • 7.1. Global Insulin biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Insulin biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Insulin biosimilars Market

  • 8.1. Asia-Pacific Insulin biosimilars Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Insulin biosimilars Market

  • 9.1. China Insulin biosimilars Market Overview
  • 9.2. China Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Insulin biosimilars Market

  • 10.1. India Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Insulin biosimilars Market

  • 11.1. Japan Insulin biosimilars Market Overview
  • 11.2. Japan Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Insulin biosimilars Market

  • 12.1. Australia Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Insulin biosimilars Market

  • 13.1. Indonesia Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Insulin biosimilars Market

  • 14.1. South Korea Insulin biosimilars Market Overview
  • 14.2. South Korea Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Insulin biosimilars Market

  • 15.1. Western Europe Insulin biosimilars Market Overview
  • 15.2. Western Europe Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Insulin biosimilars Market

  • 16.1. UK Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Insulin biosimilars Market

  • 17.1. Germany Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Insulin biosimilars Market

  • 18.1. France Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Insulin biosimilars Market

  • 19.1. Italy Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Insulin biosimilars Market

  • 20.1. Spain Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Insulin biosimilars Market

  • 21.1. Eastern Europe Insulin biosimilars Market Overview
  • 21.2. Eastern Europe Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Insulin biosimilars Market

  • 22.1. Russia Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Insulin biosimilars Market

  • 23.1. North America Insulin biosimilars Market Overview
  • 23.2. North America Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Insulin biosimilars Market

  • 24.1. USA Insulin biosimilars Market Overview
  • 24.2. USA Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Insulin biosimilars Market

  • 25.1. Canada Insulin biosimilars Market Overview
  • 25.2. Canada Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Insulin biosimilars Market

  • 26.1. South America Insulin biosimilars Market Overview
  • 26.2. South America Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Insulin biosimilars Market

  • 27.1. Brazil Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Insulin biosimilars Market

  • 28.1. Middle East Insulin biosimilars Market Overview
  • 28.2. Middle East Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Insulin biosimilars Market

  • 29.1. Africa Insulin biosimilars Market Overview
  • 29.2. Africa Insulin biosimilars Market, Segmentation By Biosimilars Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Insulin biosimilars Market, Segmentation By Disease Indication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Insulin biosimilars Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Insulin biosimilars Market Competitive Landscape And Company Profiles

  • 30.1. Insulin biosimilars Market Competitive Landscape
  • 30.2. Insulin biosimilars Market Company Profiles
    • 30.2.1. Eli Lilly and Company
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Boehringer Ingelheim GmbH
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Pfizer Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Biocon Ltd.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Insulin biosimilars Market Competitive Benchmarking

32. Global Insulin biosimilars Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Insulin biosimilars Market

34. Insulin biosimilars Market Future Outlook and Potential Analysis

  • 34.1 Insulin biosimilars Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Insulin biosimilars Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Insulin biosimilars Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer